GYN cancers

Question 1

Parp inhibitors approval in ovarian

Answer 1

olaparib 4th line therapy with BRCA mutation

Question 2

hereditary nonpolyposis colorectal cancer (HNPCC)

Answer 2

Women from hereditary nonpolyposis colorectal cancer (HNPCC) families have an increased risk of both endometrial cancer and ovarian cancer. There are a number of defined mutations in DNA mismatch repair genes associated with the HNPCC syndrome. Tumors associated with HNPCC typically show loss of mismatch repair protein expression on immunohistochemistry (IHC). Such a finding on IHC would prompt the need for genetic testing for HNPCC mutations.

Question 3

metastatic cervical cancer treatment

Answer 3

cis/taxol/bev

Question 4

cervical cancer <4cm

Answer 4

surgery and RPLND.

follow cis RT if high features

Question 5

cervical cancer>4cm

Answer 5

RT with cisplatin

Question 6

endometrial cancer stage 1A and 1B
2
3
4

Answer 6

1A watched (less than50% myometrium)
1B controversial IVRT +/-chemo
2 controversial
3 and 4 do carbo taxol dont add bev